Table 3.
Respiratory Related Medications During 15 Months Following Index
| Respiratory Medications, n (%) | All patients (n=51,349) | Patients without visits (n=36,020) | Patients with visits (n=15,329) |
|---|---|---|---|
| ICS mono inhaler | 21,456 (41.8) | 12,428 (36.8) | 9028 (51.4) |
| ICS/LABA combinations | 18,241 (35.5) | 10,744 (31.8) | 7497 (42.7) |
| ICS/LABA/LAMA combinations | 3 (0.0) | 2 (0.0) | 1 (0.0) |
| Any ICS containing inhaler | 36,210 (70.5) | 21,607 (64.0) | 14,603 (83.1) |
| LABA | 5474 (10.7) | 3060 (9.1) | 2414 (13.7) |
| LAMA | 2499 (4.9) | 1649 (4.9) | 850 (4.8) |
| SABA | 23,790 (46.3) | 14,095 (41.7) | 9695 (55.2) |
| Leukotriene modifiers | 4710 (9.2) | 2301 (6.8) | 2409 (13.7) |
| Any oral corticosteroids | 9823 (19.1) | 7073 (20.9) | 2750 (15.6) |
| Regular oral corticosteroids* | 1275 (2.5) | 1019 (3.0) | 256 (1.5) |
| N-acetylcysteine | 6617 (12.9) | 4209 (12.5) | 2408 (13.7) |
| Nasal corticosteroids | 14,256 (27.8) | 8661 (25.6) | 5595 (31.8) |
Note: Medications claimed from pharmacy *Defined as at least 4 collections.